Monteris Medical
- Industry
- Medical Devices
- Founded Year
- 1999
- Headquarters
- Minnetonka, MN, USA
- Employee Count
- 120
Key People
- Martin Emerson - President and CEO
- James Erickson - Chief Financial Officer
- Richard Tyc - Vice President, Technology and Advanced Development
- Eric Andrews - Vice President of Engineering
- Lisa Hayden - Vice President
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant backgrounds in medical technology and business management.
Martin Emerson, the President and CEO, has a strong track record in the medical device industry. The presence of seasoned executives in key roles enhances the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: Monteris Medical addresses a critical need for minimally invasive treatment options for brain tumors and drug-resistant epilepsy.
Traditional open brain surgeries carry high risks and longer recovery times. Monteris Medical's NeuroBlate System offers a minimally invasive alternative, providing patients with safer options and potentially better outcomes.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for minimally invasive neurosurgical devices has multiple players, though Monteris Medical maintains a competitive position.
The neurosurgical device market includes several companies offering similar technologies. Monteris Medical's success will depend on differentiating its products and demonstrating superior clinical outcomes.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology involves complex procedures but is well-established and manageable.
MRI-guided laser ablation is a sophisticated procedure; however, Monteris Medical has developed a system that integrates seamlessly into existing clinical workflows, reducing technical barriers to adoption.
- Patent
-
Aspect: Strong
Summary: Monteris Medical holds a robust portfolio of patents protecting its core technologies.
A strong patent portfolio safeguards Monteris Medical's innovations, preventing competitors from easily replicating their technology and ensuring a unique market position.
- Financing
-
Aspect: Well-funded
Summary: The company has secured substantial funding from reputable investors, supporting its growth and development initiatives.
With a total funding of approximately $143.1 million, including a recent $73 million round led by InnovaHealth Partners, Monteris Medical is well-capitalized to advance its commercial, clinical, and product development priorities.
- Regulatory
-
Aspect: 510k/PMA
Summary: The NeuroBlate System has received FDA clearance, facilitating its market entry.
FDA clearance indicates that the NeuroBlate System meets safety and efficacy standards, allowing Monteris Medical to market its product in the United States and build trust among healthcare providers and patients.
Opportunity Rollup
- Odds of Success
- 4.3
- Peak Market Share
- 5.9
- Segment CAGR
- 4.9%
- Market Segment
- Neurology Devices
- Market Sub Segment
- Minimally Invasive Neurosurgical Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.30 |
| 2 | 0.88 |
| 3 | 2.06 |
| 4 | 4.13 |
| 5 | 5.90 |
Key Takeaway
Monteris Medical is well-positioned in the growing market for minimally invasive neurosurgical devices, supported by a strong team, robust funding, and a clear clinical need.